Abstract: Described are antigen specific and antigen non-specific means of suppressing development of Type 1 Diabetes in a mammal through administration of exosomes, microvesicles or apoptotic bodies from monocytic lineage cells that have been reprogrammed by contact with mesenchymal stem cells and/or mesenchymal stem cell conditioned media. In one embodiment, the invention provides administration of exosomes that have been generated from monocytic cells that have been loaded with tolerogenic antigens and/or epitopes. In another embodiment the invention provides administration of allogeneic myeloid derived exosomes that are loaded with tolerogenic antigens. In another embodiment the invention provides means of stimulating exosome release in vivo from allogeneic cells that have been administered to the patient in need of treatment.

Abstract: The teleoperations system assigns move assignments to specific vehicles instead of directly to different teleoperators. Instead of operating a specific vehicle for an entire day, the teleoperator instead selects (or is assigned) move assignments and is connected to the vehicle associated with the move assignment. The teleoperator then performs the move assignment for that particular vehicle and then selects (or is assigned) the next move assignment. The next assignment may be associated with the same vehicle or an entirely different vehicle. A drive fulfillment system provides teleoperators with real-time feedback on their current location, detailed information on materials available nearby, access to camera feeds for identifying materials in transit, and the ability to determine their location based on the vehicle's position.

Abstract: The present disclosure is drawn to compositions, combinations of compounds, and methods of treating a cancer or neoplasia, including disrupting activity of telocytes associated with the cancer.

Abstract: Presented herein are systems and methods for automated analysis of patient data. More particularly, in certain embodiments, the invention relates to systems and methods for predicting the context of a particular phrase (e.g. the name of a diagnosis/condition) in a clinical record of a patient using a reportability classifier. In another aspect, the invention relates to systems and methods for automatically identifying a potential care gap and/or adverse health trend for a patient from clinical data.

Abstract: Provided herein are 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide and 4-([1,2,4]triazolo[1,5-a]pyridin-7-yl)thiophene-2-carboxamide derivatives. Such compounds are useful, for example, for the treatment and/or prevention of neurodegenerative diseases or disorders such as ophthalmological neurodegenerative disorders. This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: Disclosed are means of inducing and accelerating neurological recovery subsequent to a stroke through administration of amniotic fluid derived stem cells. In one embodiment stem cells are isolated from amniotic fluid and expanded under conditions allowing for expression of SSEA3, SSEA4, Tra1-60, Tra1-81, Tra2-54, Oct-4 and CD105. Said cells are subsequently administered into a patient having undergone a stroke, so as to induce direct regeneration (through transdifferentiation and replacement of neural tissue), as well as indirect regeneration (through production of growth factors that augment endogenous regenerative mechanisms while inhibiting degenerative mechanisms). In some embodiments factors produced by said amniotic fluid stem cells may be utilized instead of cells themselves. Said factors may include proteins, peptides, conditioned media, exosomes, or microvesicles.

Abstract: Presented herein are systems and methods for automated analysis of patient data. More particularly, in certain embodiments, the invention relates to systems and methods for predicting the context of a particular phrase (e.g. the name of a diagnosis/condition) in a clinical record of a patient using a reportability classifier. In another aspect, the invention relates to systems and methods for automatically identifying a potential care gap and/or adverse health trend for a patient from clinical data.

Abstract: An exemplary receive antenna having a conductive surface. The conductive surface includes an aperture configured to operate as a slot antenna, and one or more amplifiers or buffer amplifiers is electrically connected across the aperture. At least one feed is connected between the one or more amplifiers and the aperture. An input impedance ZB of each of the one or more amplifiers at the at least one feed location is lower than 0.5× an impedance of the aperture ZA at a first resonance frequency.

Abstract: Provided herein are 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide and 4-([1,2,4]triazolo[1,5-a]pyridin-7-yl)thiophene-2-carboxamide derivatives. Such compounds are useful, for example, for the treatment and/or prevention of neurodegenerative diseases or disorders such as ophthalmological neurodegenerative disorders. This disclosure also features compositions containing the same as well as methods of using and making the same.

Abstract: Disclosed are means, methods and compositions of matter useful for prevention and/or reversion of type 1 diabetes by upregulation of myeloid suppressor cell activity in a mammal suffering from and/or at risk of developing type 1 diabetes. In one embodiment the invention teaches administration of immune cells that have been conditioned by exposure to regenerative cells, and/or cultured in the presence of factors produced from regenerative cells. In one embodiment said regenerative cells are umbilical cord derived mesenchymal stem cells. In one embodiment, immune cells that have been exposed to said regenerative cells are administered together with agents known to enhance myeloid suppressor cell activity. In another embodiment immune cells are administered together with exogenous myeloid suppressor cells.

Abstract: Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

Abstract: The present disclosure is directed to a kit for evaluating system inertness. The kit includes a positive control comprising a metal interacting moiety, and a negative control that does not contain a metal interacting moiety. In some embodiments the kit also includes a container to hold a system suitability solution (e.g., an equimolar mixture of the positive control and the negative control).

Abstract: An exemplary receive antenna having a conductive surface. The conductive surface includes an aperture configured to operate as a slot antenna, and one or more amplifiers or buffer amplifiers is electrically connected across the aperture. At least one feed is connected between the one or more amplifiers and the aperture. An input impedance ZB of each of the one or more amplifiers at the at least one feed location is lower than 0.5× an impedance of the aperture ZA at a first resonance frequency.

Abstract: A particulate lyophilized platelet lysate composition suitable for use as a cell culture medium can include growth factors, cytokines, and chemokines released from lysis of source platelets, wherein cellular debris from the source platelets is removed (partially or fully) by filtration. The growth factors, cytokines, and chemokines are lyophilized to form a particulate lyophilized platelet lysate composition.

Abstract: Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

Abstract: The present disclosure is directed to a kit for evaluating system inertness. The kit includes a positive control comprising a metal interacting moiety, and a negative control that does not contain a metal interacting moiety. In some embodiments the kit also includes a container to hold a system suitability solution (e.g., an equimolar mixture of the positive control and the negative control).

Abstract: Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

Abstract: A method for processing a sample in a container includes introducing the sample to the container. A cap is applied to the container. The cap contains a plurality of beads. The plurality of beads is mixed with the sample. The plurality of beads is separated from the sample. Subsequent to removing the plurality of beads, a further process is initiated.

Abstract: Methods of reducing death, destruction or rejection of beta islets along with peripheral receptors in patients before they have diabetes, wherein said method comprising the steps of: a) obtaining a patient in need of immune cell therapy; b) administering to said patient one or more immunomodulatory cells; c) assessing the prevention and transition to diabetes.

Abstract: Methods of improving muscle receptor sensitivity to insulin muscle receptors, reducing death, destruction or rejection of beta islets in patients having insulin dependent diabetes, wherein said method comprising the steps of: a) obtaining a patient in need of immune cell therapy; b) administering to said patient immunomodulatory cells; c) assessing the prevention and transition to diabetes requiring insulin.